Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?
Bielack
S S
SS
Abteilung für pädiatrische Hämatologie & Onkologie, Universitätskinderklinik Hamburg, Germany.
Erttmann
R
R
Kempf-Bielack
B
B
Winkler
K
K
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin